Effectiveness of Disinfectants Against *Candida auris* and Other *Candida* Species

Jennifer L. Cadnum, BS;¹ Aaron A. Shaikh, BS;² Christina T. Piedrahita, BS;¹ Thriveen Sankar, MBA;¹ Annette L. Jencson, CIC;³ Emily L. Larkin, BS;³,⁴ Mahmoud A. Ghannoum, PhD;³,⁴ Curtis J. Donskey, MD²,⁵

Contaminated surfaces are a suspected source for dissemination of the globally emerging pathogen *Candida auris*. In laboratory testing, sporicidal and improved hydrogen peroxide disinfectants were highly effective against *C. auris*, *C. glabrata*, and *C. albicans*. The widely used quaternary ammonium disinfectants exhibited relatively poor activity against all of the *Candida* species.

*Infect Control Hosp Epidemiol* 2017;38:1240–1243

*Candida auris* is a globally emerging pathogen that is often resistant to multiple antifungal agents.¹⁻³ In several reports, *C. auris* has been recovered from the hospital environment, suggesting that contaminated surfaces may be a source of transmission.¹,² The Centers for Disease Control and Prevention (CDC) has therefore recommended daily and post-discharge disinfection of surfaces in rooms of patients with *C. auris* infection.⁴ Moreover, the use of an Environmental Protection Agency (EPA)–registered, hospital-grade disinfectant effective against *Clostridium difficile* spores was specified.⁴ However, nonsporicidal disinfectants are widely used and many have an EPA-registered antifungal claim.⁵ No hospital disinfectants are registered for use specifically against *C. auris*, and it is not known whether *C. auris* is less susceptible to disinfectants than other *Candida* species.

**METHODS**

We evaluated the efficacy of 9 commercial disinfectants and the common household disinfectant white distilled vinegar (>5% acetic acid, pH 2.0) against *C. auris*, *C. albicans*, and *C. glabrata*. For comparison, 3 strains of methicillin-resistant *Staphylococcus aureus* (MRSA) were tested. The 5 *C. auris* strains have been described previously⁵⁻⁶; the strains included 3 multidrug-resistant clinical isolates (MRL#31102 and #31103 and CBS#12373) and 2 drug-susceptible isolates (CBS#10913 and CDC strain AR-BANK#0381). The 4 *C. albicans* strains included American Type Culture Collection (ATCC) strains SC#5314 and #10231 and 2 clinical strains from the Center for Medical Mycology, Cleveland, Ohio (MRL#32249 and #32708). The *C. glabrata* clinical strains were MRL#31820, #34870, and #9547. The 3 MRSA strains included ATCC strain 43,300 and 2 clinical isolates.

The disinfectants and their contact times are shown in Table 1. For the commercial products, the contact times were based on the manufacturer’s recommendations except for Clorox Healthcare hydrogen peroxide cleaner disinfectant (ie, a 1-minute exposure was used rather than the 3 minutes recommended for *C. albicans* based on preliminary experiments that demonstrated excellent activity with the shorter exposure time). Testing of disinfectant efficacy was conducted according to the American Society for Testing and Materials (ASTM) Standard quantitative carrier disk test method (ASTM E2197-11).⁷ To simulate the presence of organic material, 5% fetal calf serum (Remel, Lenexa, KS) was added to the inoculum. The steel-disk carriers were inoculated with ~10⁶ colony-forming units (CFUs) of washed *Candida* species or MRSA from an overnight culture; the test was not considered valid unless a minimum of 10⁵ CFU was recovered from control carriers. After disinfectant exposure, carriers were neutralized with Dey-Engley neutralizer (Remel), except for Oxivir Tb (Diversey, Charlotte, NC) and Clorox Healthcare hydrogen peroxide cleaner disinfectant (Clorox, Oakland, CA), which were neutralized with 0.1% Tween 80 and 3% glycine in 0.85% NaCl. Serial dilutions were plated onto Sabouraud dextrose agar (Becton-Dickinson, Sparks, MD) and incubated at 37°C for 72 hours. Log reductions were calculated by subtracting viable organisms recovered after disinfectant exposure versus deionized water controls. Experiments were performed in triplicate.

To determine whether different test methods might yield different results for a quaternary ammonium compound, we compared reductions of the *Candida* species and MRSA for Virex II 256 using ASTM E-2197-11 and the AOAC (Association of Official Agricultural Chemists) Official Method 961.02 for Germicidal Spray Products.⁸ For this comparison, we included tests with a lower inoculum resulting in 10⁴ CFU recovered from control carriers. The rationale for testing the reduced inoculum was that the EPA product performance test guideline OCSPP 810.2200 for disinfectants with fungicidal claims recommends that carriers have a concentration of 10⁵ to 10⁶ CFU per carrier.⁹ In the AOAC method, glass microscope slides are used as carriers and the inoculum is spread to cover approximately 1 square inch. For all experiments, log reductions were compared for different disinfectants using linear modeling with post hoc Tukey’s adjustment for multiple comparisons. Data were analyzed using SPSS statistical software version 10.0 (SPSS, Chicago, IL).

**RESULTS**

Figure 1 shows the mean reductions for the disinfectants using the ASTM method. For MRSA, each of the disinfectants reduced recovery by ~6 log₈ CFU. The data for each of the *Candida* species was pooled because there were no significant
Table 1. Characteristics of the Disinfectants Tested

<table>
<thead>
<tr>
<th>Disinfectant</th>
<th>Active Components</th>
<th>Contact Time&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Sporicidal Claim&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Candida albicans Claim&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clorox Healthcare bleach germicidal cleaner</td>
<td>Sodium hypochlorite 0.65%</td>
<td>1 min</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Clorox Healthcare Fuzion cleaner disinfectant</td>
<td>Sodium hypochlorite 0.39%</td>
<td>1 min</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Clorox germicidal bleach (1:10 dilution)</td>
<td>Sodium hypochlorite 0.825% when diluted</td>
<td>1 min</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>OxyCide daily disinfectant</td>
<td>Peracetic acid 1200 parts per million, hydrogen peroxide &lt;1%, acetic acid</td>
<td>3 min</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Clorox Healthcare hydrogen peroxide cleaner disinfectant</td>
<td>Hydrogen peroxide 1.4%</td>
<td>1 min&lt;sup&gt;d&lt;/sup&gt;</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Oxivir Tb</td>
<td>Hydrogen peroxide 0.5%</td>
<td>10 min</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>White distilled vinegar</td>
<td>Acetic acid &gt;5% (pH 2.0)</td>
<td>3 min&lt;sup&gt;e&lt;/sup&gt;</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Purell healthcare surface disinfectant</td>
<td>Ethyl alcohol 29.4%</td>
<td>30 s</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Lysol all-purpose cleaner</td>
<td>Alkyl dimethyl benzyl ammonium chlorides</td>
<td>10 min</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Virex II 256</td>
<td>Didecyl dimethyl ammonium chloride, n-Alkyl dimethyl benzyl ammonium chloride</td>
<td>10 min</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

<sup>a</sup>Contact time for disinfectants based on manufacturers’ recommendations for Candida albicans unless otherwise specified.

<sup>b</sup>Environmental Protection Agency–registered claim against Clostridium difficile spores.

<sup>c</sup>Environmental Protection Agency–registered claim against Candida albicans.

<sup>d</sup>A 1-minute exposure was used, but the claim is based on a 3-minute exposure.

<sup>e</sup>There is no established contact time for vinegar.

Figure 1. Mean log reductions for each of the disinfectants against the 3 Candida species and MRSA using the American Society for Testing and Materials (ASTM) Standard Quantitative Carrier Disk Test Method (ASTM E-2197-02).<sup>7</sup> Log reductions were calculated by subtracting viable organisms recovered after exposure to the disinfectants versus deionized water controls. Vinegar, Purell Healthcare Surface Disinfectant, and the 2 quaternary ammonium disinfectants were significantly less effective against the Candida species than against MRSA (P ≤ .02). Error bars show standard error. MRSA, methicillin-resistant Staphylococcus aureus.
differences in reductions for different strains. The 3 bleach disinfectants, OxyCide, Clorox Healthcare hydrogen peroxide cleaner disinfectant, and Oxivir TB consistently reduced the Candida species by ≥5 log_{10} CFU, and there were no significant differences in reductions for the Candida species and MRSA (P > .05). Vinegar, Purell Healthcare surface disinfectant (Gojo, Akron, OH), and the 2 quaternary ammonium disinfectants were significantly less effective against Candida species than against MRSA (P ≤ .02). There were no significant differences in efficacy against C. auris versus the other Candida species.

Compared to the ASTM method, the AOAC method resulted in significantly greater measured log reductions (mean ± SE) for Virex II 256 against C. albicans (3.3 ± 0.4 versus 0.5 ± 0.4), C. glabrata (3.8 ± 0.4 vs 0.4 ± 0.2), and C. auris (2.2 ± 2 vs 0.7 ± 0.3) (P < .05 for each comparison), but not MRSA (ie, ~6 log_{10}CFU reductions with both methods), when the inoculum was 10^6 CFUs per carrier (P < .05 for each comparison).

For the ASTM E2197-11 method, reducing the inoculum such that 10^7 CFUs were recovered from the control carriers significantly enhanced the measured reduction in Candida species achieved by Virex II 256 (~3 vs 0.5 to 2 log reduction; P < .01). For the AOAC method, a similar reduction in the inoculum resulted in 4 log reductions in each of the Candida species (data not shown).

DISCUSSION

Many disinfectants have an EPA-registered fungal claim based on efficacy against C. albicans or Trichophyton mentagrophytes. However, interim recommendations from the CDC have specified that an EPA-registered hospital-grade disinfectant effective against C. difficile spores be used for C. auris. Our results provide support for that recommendation but also demonstrate that nonsporicidal improved hydrogen peroxide disinfectants are highly active against Candida species, including C. auris. There was no evidence that C. auris has greater resistance to disinfectants than do other Candida species.

The relatively poor activity of the quaternary ammonium disinfectants against all Candida species is concerning because these agents are widely used. In contrast to MRSA, we found that differences in test methods may markedly impact the measured efficacy of quaternary ammonium disinfectants against Candida species. Our results suggest that factors such as use of a smaller organism inoculum and spreading of the inoculum may enhance the measured reductions. In that regard, it should be noted that the EPA has recently released interim guidance for testing the efficacy of liquid antimicrobials against C. auris; the recommended methods are similar to the ASTM method used in our study, and both methods yield similar results (unpublished data).

It is possible that the environment may be an under-appreciated reservoir for the spread of Candida species other than C. auris. In a recent study, we demonstrated that C. auris and other Candida species have a similar propensity to survive on surfaces, and Candida species were frequently recovered from the hospital environment, particularly from moist surfaces. Moreover, previous studies have implicated the environment as a potential source for transmission of Candida species.

Our study has some limitations. We studied only 2 quaternary ammonium disinfectants and cannot exclude the possibility that other quaternary ammonium compounds may have greater activity. We did not assess the efficacy of the disinfectants on hospital surfaces. It is possible that quaternary ammonium compounds may exhibit greater efficacy on real-world surfaces if smaller numbers of Candida species are present.

ACKNOWLEDGMENTS

Financial support: This work was funded by a Merit Review grant (grant no. BX002944-01A1) from the Department of Veterans Affairs to CJD.

Potential conflicts of interest: CJD has received research grants from Merck, GOJO, Altapure, EcoLab, and Clorox and serves on advisory boards for 3M and Synthetic Biologics. All other authors report no conflicts of interest relevant to this article.

Affiliations: 1. Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio; 2. Case Western Reserve University School of Medicine, Cleveland, Ohio; 3. Center for Medical Mycology, Case Western Reserve University, Cleveland, Cleveland, Ohio; 4. University Hospitals Cleveland Medical Center, Cleveland, Ohio; 5. Geriatric Research, Education, and Clinical Center, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio

Address correspondence to Curtis J. Donskey, MD, Geriatric Research, Education, and Clinical Center, 11101 West Boulevard, Cleveland, Ohio 44106 (Curtis.Donskey@va.gov).

Received May 8, 2017; accepted July 5, 2017; electronically published August 10, 2017

© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2017/3810-0015. DOI: 10.1017/ice.2017.162

REFERENCES


